These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20524819)

  • 1. Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone.
    Pontikoglou C; Papadaki HA
    Hemoglobin; 2010 Jun; 34(3):291-304. PubMed ID: 20524819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Necrotizing stomatitis: a possible periodontal manifestation of deferiprone-induced agranulocytosis.
    Tewari S; Tewari S; Sharma RK; Abrol P; Sen R
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Oct; 108(4):e13-9. PubMed ID: 19778731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idiosyncratic drug-induced agranulocytosis or acute neutropenia.
    Andrès E; Maloisel F
    Curr Opin Hematol; 2008 Jan; 15(1):15-21. PubMed ID: 18043241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferiprone-associated myelotoxicity.
    al-Refaie FN; Wonke B; Hoffbrand AV
    Eur J Haematol; 1994 Nov; 53(5):298-301. PubMed ID: 7813710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Febrile neutropenia and hemorrhagic stroke in a thalassemia major patient.
    Sheikh-Taha M; Koussa S; Inati A; Taher A
    Hemoglobin; 2007; 31(4):499-501. PubMed ID: 17994386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-chemotherapy drug-induced agranulocytosis.
    Garbe E
    Expert Opin Drug Saf; 2007 May; 6(3):323-35. PubMed ID: 17480181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia.
    Botzenhardt S; Sing CW; Wong IC; Chan GC; Wong LY; Felisi M; Rascher W; Ceci A; Neubert A
    Curr Drug Saf; 2016; 11(2):137-44. PubMed ID: 26419768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deferiprone-induced agranulocytosis: 20 years of clinical observations.
    Tricta F; Uetrecht J; Galanello R; Connelly J; Rozova A; Spino M; Palmblad J
    Am J Hematol; 2016 Oct; 91(10):1026-31. PubMed ID: 27415835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Idiosyncratic drug-induced agranulocytosis].
    Andrès E; Maloisel F;
    Rev Med Interne; 2006 Mar; 27(3):209-14. PubMed ID: 16043267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis.
    Elalfy M; Wali YA; Qari M; Al Damanhouri G; Al-Tonbary Y; Yazman D; Al Hawsawi Z; Karakas Z; Kilinc Y; Yesilipek MA; Badr M; Elsafy U; Salama M; Abdel Rahman Y; Shebl S; Stilman A; Toiber Temin N; Tricta F
    Pediatr Blood Cancer; 2014 May; 61(5):879-84. PubMed ID: 24376176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profile of the oral iron chelator deferiprone: a multicentre study.
    Cohen AR; Galanello R; Piga A; Dipalma A; Vullo C; Tricta F
    Br J Haematol; 2000 Feb; 108(2):305-12. PubMed ID: 10691860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The controversial role of deferiprone in the treatment of thalassemia.
    Richardson DR
    J Lab Clin Med; 2001 May; 137(5):324-9. PubMed ID: 11329529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agranulocytosis due to deferiprone: a case report with cytomorphological and functional bone marrow examination.
    Masera N; Tavecchia L; Longoni DV; Maglia O; Biondi A; Masera G
    Blood Transfus; 2011 Oct; 9(4):462-5. PubMed ID: 21839013
    [No Abstract]   [Full Text] [Related]  

  • 14. Agranulocytosis and thrombocytopenia, Blackfan-Diamond anaemia, and oral chelation.
    Alter BP
    Lancet; 1990 Apr; 335(8695):970. PubMed ID: 1970037
    [No Abstract]   [Full Text] [Related]  

  • 15. Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial.
    Hoffbrand AV; Bartlett AN; Veys PA; O'Connor NT; Kontoghiorghes GJ
    Lancet; 1989 Aug; 2(8660):457. PubMed ID: 2569644
    [No Abstract]   [Full Text] [Related]  

  • 16. Deferiprone: new preparation. Poorly assessed.
    Prescrire Int; 2000 Oct; 9(49):131-5. PubMed ID: 11603411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agranulocytosis with deferiprone treatment of superficial siderosis.
    Huprikar N; Gossweiler M; Callaghan M; Bunge P
    BMJ Case Rep; 2013 Aug; 2013():. PubMed ID: 23925681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron chelation therapy.
    Hoffbrand AV; Wonke B
    J Intern Med Suppl; 1997; 740():37-41. PubMed ID: 9350180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of deferiprone for iron chelation in patients with transfusion-dependent thalassaemia.
    Jamuar SS; Lai AH; Tan AM; Chan MY; Tan ES; Ng IS
    J Paediatr Child Health; 2011 Nov; 47(11):812-7. PubMed ID: 21902752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload.
    ElAlfy MS; Sari TT; Lee CL; Tricta F; El-Beshlawy A
    J Pediatr Hematol Oncol; 2010 Nov; 32(8):601-5. PubMed ID: 20921906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.